VIDEO · 12 DECEMBER 2012

Measuring The Return From Pharmaceutical Innovation 2012 (Video Content)

Deloitte

Explore more from Deloitte

This Deloitte report is the third in an annual series exploring the pharmaceutical industry’s performance in generating a return from its investment in new product innovation.

United KingdomStrategy

Deloitte Life Sciences & Healthcare Group

Author LinkedIn connections

Is R&D earning its investment?

Background

This Deloitte report is the third in an annual series exploring the pharmaceutical industry's performance in generating a return from its investment in new product innovation. For the last three years Deloitte and Thomson Reuters have analysed the performance of the top 12 life sciences companies by estimating the projected financial returns from the investment in their late stage pipelines. The cohort of companies comprises the 12 publicly-listed companies reporting the highest absolute research and development (R&D) spend for 2008-2009. The late stage pipeline includes those compounds which are either in Phase III development or submitted for approval.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

Register for freeORLog in

Related Articles

Atom Valley Completes Major Milestone

United KingdomStrategy

Autumn Statement Outlook: Why Businesses Must Balance Caution With Opportunity

United KingdomStrategy

Lester Aldridge LLP

Non-Competes: Back On The Agenda In The UK

United KingdomStrategy

FinTech Global FS Regulatory Round-up - W/e 9 October 2026

Herbert Smith Freehills Kramer LLP

Practical AI For CFOs

United KingdomStrategy

AlixPartners Asia LLC

Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics

Read more about

See more popular content from

Strategy

TLT's AI Brief: October 2026

September brought significant regulatory developments in AI governance, with new frameworks emerging across the UK, Europe, and the United States. From the UK government's AI Risk Management Toolkit to Florida's unprecedented legal action against OpenAI, regulators and policymakers are working to ensure AI capabilities are matched by robust safeguards and accountability measures.

United KingdomStrategy

Preparing For The EU Cyber Resilience Act: Key Reporting Obligations From 11 September 2026

The EU's Cyber Resilience Act introduces mandatory cybersecurity reporting obligations for manufacturers of digital products starting September 2026, requiring notification of actively exploited vulnerabilities and severe incidents within strict timeframes. Companies must establish procedures to identify and report security events to national Computer Security Incident Response Teams, with potential fines reaching €15 million or 2.5% of global turnover for non-compliance.

United KingdomStrategy

Goodwin Procter LLP

Using AI In Your Business? New Rules On What You Must Disclose

The EU AI Act's transparency rules now require businesses using AI systems to disclose when customers interact with artificial intelligence or encounter AI-generated content.

United KingdomStrategy

Logan & Partners

2026 Legal AI Survey Report: Legal AI Is Everywhere, Now Comes The Hard Part.

Legal AI has rapidly proliferated across in-house legal teams, appearing in budgets and workflows everywhere, yet a striking gap has emerged between adoption and effective implementation. While nearly every legal department now uses AI tools, only a small fraction has successfully scaled their deployment, and the vast majority cannot determine if their investments are delivering value.

European Commission Proposes European Innovation Act

The European Commission has unveiled a European Innovation Act designed to strengthen the EU's innovation ecosystem by addressing two critical challenges: limited access to finance for IP-rich businesses and fragmented regulatory frameworks across Member States. The proposal introduces measures including a common IP valuation framework, streamlined R&D procurement procedures, and harmonized regulatory sandboxes to help startups and scaleups commercialize their innovations more effectively.

European UnionStrategy

The SRA’s AI Warning Notice: A Regulatory Wake-up Call, Not A Reason To Step Back

The Solicitors Regulation Authority has issued a warning notice on AI misuse in legal practice, clarifying what responsible adoption looks like. While recognizing AI's benefits for document review, drafting, and research, the regulator emphasizes that solicitors remain accountable for their work regardless of the tools used, requiring proper governance, human oversight, and professional judgment to manage risks like hallucinated citations and confidentiality breaches.

United KingdomStrategy

EU Cyber Resilience Act Countdown: 11 September 2026 Incident/Vulnerability Reporting Deadline Less Than 100 Days Away

The EU Cyber Resilience Act (CRA) is an EU product cybersecurity law for connected products (formally, “products with digital elements” under the CRA) commercialized in the EU; it entered into force on 10 December 2024...

United KingdomStrategy

Crowell & Moring LLP

AI Is Not Replacing Lawyers — It Is Replacing Inefficiency

For two years, the legal profession has faced predictions that AI will make lawyers obsolete, but this narrative fundamentally misunderstands the relationship between technology and legal judgment.

United KingdomStrategy

Moneylaundering And Environment

United KingdomStrategy

Law Commission Recommends Major Reform Of Burial And Cremation Law: What Families Need To Know

This content appears to be a placeholder or test page containing only the text 'OK'. Without substantive information, it's not possible to determine the article's premise, purpose, or subject matter.

United KingdomStrategy

Anthony Gold Solicitors LLP